Treatment for COVID-19—a cohort study from Northern Italy

Autor: Guglielmetti, Lorenzo, Aschieri, Daniela, Kontsevaya, Irina, Calabrese, Francesco, Donisi, Alessandra, Faggi, Alberto, Ferrante, Patrizia, Fronti, Elisa, Gerna, Laura, Leoni, Maria Cristina, Paolillo, Franco, Ratti, Giovanna, Ruggieri, Alessandro, Sacchini, Daria, Scotti, Marta, Valdatta, Caterina, Stabile, Marco, Taliani, Gloria, Codeluppi, Mauro
Přispěvatelé: Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Piacenza Hospital, Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière] (CNR-MyRMA), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Forschungszentrum Borstel - Research Center Borstel, Lübeck University of Applied Sciences, Campus Universitat Illes Balears, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), HAL-SU, Gestionnaire, Centre d'Immunologie et de Maladies Infectieuses (CIMI), Centre National de Référence des Mycobactéries et de la Résistance aux Antituberculeux [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Società Italiana di Malattie Infettive e Tropicali
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Scientific Reports
Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-00243-4⟩
Scientific Reports, Nature Publishing Group, 2021, 11 (1), ⟨10.1038/s41598-021-00243-4⟩
Scientific Reports, Vol 11, Iss 1, Pp 1-4 (2021)
Digital.CSIC. Repositorio Institucional del CSIC
instname
ISSN: 2045-2322
DOI: 10.1038/s41598-021-00243-4⟩
Popis: Multicentre, retrospective cohort study with multivariable Cox proportional-hazards modelling and survival-time inverse-probability-weighting, evaluating the impact of different treatments on survival of proven COVID-19 patients admitted to two Hospitals in the province of Piacenza, Italy. Use of tocilizumab and of high doses of low molecular weight heparin, but not of antivirals (either alone or in combination), azithromycin, and any corticosteroid, was independently associated with lower mortality. Our results support further clinical evaluation of high doses of low molecular weight heparin and tocilizumab as COVID-19 therapeutics.
The work of the corresponding author (LG) in the Hospital of Piacenza was supported by the Italian Society of Infectious and Tropical Diseases (SIMIT).
Databáze: OpenAIRE
Externí odkaz: